About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2006 (2006), Article ID 31372, 13 pages
http://dx.doi.org/10.1155/JBB/2006/31372
Review Article

Mitochondrial Oxidative Damage in Aging and Alzheimer's Disease: Implications for Mitochondrially Targeted Antioxidant Therapeutics

Neurogenetics Laboratory, Neurological Sciences Institute, Oregon Health & Science University, 505 NW 185th Avenue, Beaverton 97006, OR, USA

Received 8 December 2005; Revised 28 February 2006; Accepted 28 February 2006

Copyright © 2006 P. Hemachandra Reddy. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D J Selkoe, “Alzheimer's disease: genes, proteins, and therapy,” Physiological Reviews, vol. 81, no. 2, pp. 741–766, 2001. View at PubMed
  2. M P Mattson, “Pathways towards and away from Alzheimer's disease,” Nature, vol. 430, no. 7000, pp. 631–639, 2004. View at Publisher · View at Google Scholar · View at PubMed
  3. P H Reddy and S McWeeney, “Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models,” Neurobiology of Aging, 2005, September 9; [Epub ahead of print]. View at PubMed
  4. T S Anekonda and P H Reddy, “Can herbs provide a new generation of drugs for treating Alzheimer's disease?,” Brain Research. Brain Research Reviews, vol. 50, no. 2, pp. 361–376, 2005. View at PubMed
  5. P H Reddy and M F Beal, “Are mitochondria critical in the pathogenesis of Alzheimer's disease?,” Brain Research. Brain Research Reviews, vol. 49, no. 3, pp. 618–632, 2005, Epub 2005 April 19. View at Publisher · View at Google Scholar · View at PubMed
  6. P H Reddy, “Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease,” Journal of Neurochemistry, vol. 96, no. 1, pp. 1–13, 2006. View at Publisher · View at Google Scholar · View at PubMed
  7. X Zhu, H G Lee, G Casadesus, et al., “Oxidative imbalance in Alzheimer's disease,” Molecular Neurobiology, vol. 31, no. 1–3, pp. 205–217, 2005. View at Publisher · View at Google Scholar · View at PubMed
  8. R H Swerdlow and S M Khan, “A “mitochondrial cascade hypothesis” for sporadic Alzheimer's disease,” Medical Hypotheses, vol. 63, no. 1, pp. 8–20, 2004. View at Publisher · View at Google Scholar · View at PubMed
  9. P G Sullivan and M R Brown, “Mitochondrial aging and dysfunction in Alzheimer's disease,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 29, no. 3, pp. 407–410, 2005. View at PubMed
  10. J Raber, Y Huang, and J W Ashford, “ApoE genotype accounts for the vast majority of AD risk and AD pathology,” Neurobiology of Aging, vol. 25, no. 5, pp. 641–650, 2004. View at Publisher · View at Google Scholar · View at PubMed
  11. J Raber, “Androgens, apoE, and Alzheimer's disease,” Science of Aging Knowledge Environment, vol. 2004, no. 11, p. re2, 2004. View at Publisher · View at Google Scholar · View at PubMed
  12. S M de la Monte and J R Wands, “Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 45–61, 2005. View at PubMed
  13. M Kitazawa, T R Yamasaki, and F M LaFerla, “Microglia as a Potential Bridge between the Amyloid \{beta\}-Peptide and Tau,” Annals of the New York Academy of Sciences, vol. 1035, pp. 85–103, 2004. View at Publisher · View at Google Scholar · View at PubMed
  14. S Oddo, L Billings, J P Kesslak, D H Cribbs, and F M LaFerla, “Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome,” Neuron, vol. 43, no. 3, pp. 321–332, 2004. View at Publisher · View at Google Scholar · View at PubMed
  15. S Oddo, A Caccamo, L Tran, et al., “Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology,” The Journal of Biological Chemistry, vol. 281, no. 3, pp. 1599–1604, 2006, November 10; [Epub ahead of print]. View at Publisher · View at Google Scholar · View at PubMed
  16. S Oddo, A Caccamo, J D Shepherd, et al., “Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction,” Neuron, vol. 39, no. 3, pp. 409–421, 2003. View at Publisher · View at Google Scholar · View at PubMed
  17. D Morgan, M N Gordon, J Tan, D Wilcock, and A M Rojiani, “Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 9, pp. 743–753, 2005. View at PubMed
  18. J W Lustbader, M Cirilli, C Lin, et al., “ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease,” Science, vol. 304, no. 5669, pp. 448–452, 2004. View at Publisher · View at Google Scholar · View at PubMed
  19. P J Crouch, R Blake, J A Duce, et al., “Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42,” Journal of Neuroscience, vol. 25, no. 3, pp. 672–679, 2005. View at Publisher · View at Google Scholar
  20. A Nordberg, E Hellstrom-Lindahl, M Lee, et al., “Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw),” Journal of Neurochemistry, vol. 81, no. 3, pp. 655–658, 2002. View at Publisher · View at Google Scholar · View at PubMed
  21. P H Reddy, S McWeeney, B S Park, et al., “Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease,” Human Molecular Genetics, vol. 13, no. 12, pp. 1225–1240, 2004, Epub 2004 April 28. View at Publisher · View at Google Scholar · View at PubMed
  22. P H Reddy, G Mani, B S Park, et al., “Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction,” Journal of Alzheimer's Disease, vol. 7, no. 2, pp. 103–117, 2005, discussion 173-80. View at PubMed
  23. M Manczak, B S Park, Y Jung, and P H Reddy, “Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage,” Neuromolecular Medicine, vol. 5, no. 2, pp. 147–162, 2004. View at Publisher · View at Google Scholar · View at PubMed
  24. K Hirai, G Aliev, A Nunomura, et al., “Mitochondrial abnormalities in Alzheimer's disease,” Journal of Neuroscience, vol. 21, no. 9, pp. 3017–3023, 2001. View at PubMed
  25. D Schenk, R Barbour, W Dunn, et al., “Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse,” Nature, vol. 400, no. 6740, pp. 173–177, 1999. View at Publisher · View at Google Scholar · View at PubMed
  26. D Morgan, D M Diamond, P E Gottschall, et al., “A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease,” Nature, vol. 408, no. 6815, pp. 982–985, 2000. View at Publisher · View at Google Scholar · View at PubMed
  27. R B DeMattos, K R Bales, D J Cummins, J C Dodart, S M Paul, and D M Holtzman, “Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8850–8855, 2001. View at Publisher · View at Google Scholar · View at PubMed
  28. D S Gelinas, K DaSilva, D Fenili, P St George-Hyslop, and J McLaurin, “Immunotherapy for Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. suppl 2, pp. 14657–14662, 2004, Epub 2004 August 5. View at Publisher · View at Google Scholar · View at PubMed
  29. P L McGeer and E G McGeer, “The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases,” Brain Research. Brain Research Reviews, vol. 21, no. 2, pp. 195–218, 1995. View at Publisher · View at Google Scholar · View at PubMed
  30. L J Launer, “Nonsteroidal anti-inflammatory drugs and Alzheimer disease: what's next?,” The Journal of the American Medical Association, vol. 289, no. 21, pp. 2865–2867, 2003. View at Publisher · View at Google Scholar · View at PubMed
  31. L Gasparini, E Ongini, and G Wenk, “Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action,” Journal of Neurochemistry, vol. 91, no. 3, pp. 521–536, 2004. View at Publisher · View at Google Scholar · View at PubMed
  32. L Gasparini, E Ongini, D Wilcock, and D Morgan, “Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease,” Brain Research. Brain Research Reviews, vol. 48, no. 2, pp. 400–408, 2005. View at Publisher · View at Google Scholar · View at PubMed
  33. H Nakashima, T Ishihara, O Yokota, et al., “Effects of alpha-tocopherol on an animal model of tauopathies,” Free Radical Biology & Medicine, vol. 37, no. 2, pp. 176–186, 2004. View at PubMed
  34. V Conte, K Uryu, S Fujimoto, et al., “Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury,” Journal of Neurochemistry, vol. 90, no. 3, pp. 758–764, 2004. View at Publisher · View at Google Scholar · View at PubMed
  35. S Sung, Y Yao, K Uryu, et al., “Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease,” The FASEB Journal, vol. 18, no. 2, pp. 323–325, 2004. View at PubMed
  36. E Matsubara, T Bryant-Thomas, J Pacheco Quinto, et al., “Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease,” Journal of Neurochemistry, vol. 85, no. 5, pp. 1101–1108, 2003. View at Publisher · View at Google Scholar · View at PubMed
  37. R W Stackman, F Eckenstein, B Frei, D Kulhanek, J Nowlin, and J F Quinn, “Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment,” Experimental Neurology, vol. 184, no. 1, pp. 510–520, 2003. View at Publisher · View at Google Scholar · View at PubMed
  38. F Yang, G P Lim, A N Begum, et al., “Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo,” The Journal of Biological Chemistry, vol. 280, no. 7, pp. 5892–5901, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. M C Morris, L A Beckett, P A Scherr, et al., “Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 12, no. 3, pp. 121–126, 1998. View at PubMed
  40. M C Morris, D A Evans, J L Bienias, et al., “Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study,” The Journal of the American Medical Association, vol. 287, no. 24, pp. 3230–3237, 2002. View at Publisher · View at Google Scholar · View at PubMed
  41. M C Morris, D A Evans, C C Tangney, et al., “Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change,” The American Journal of Clinical Nutrition, vol. 81, no. 2, pp. 508–514, 2005. View at PubMed
  42. M Grundman, R C Petersen, S H Ferris, et al., “Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials,” Archives of Neurology, vol. 61, no. 1, pp. 59–66, 2004. View at Publisher · View at Google Scholar · View at PubMed
  43. P P Zandi, J C Anthony, A S Khachaturian, et al., “Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study,” Archives of Neurology, vol. 61, no. 1, pp. 82–88, 2004. View at Publisher · View at Google Scholar · View at PubMed
  44. N A Clarke and P T Francis, “Cholinergic and glutamatergic drugs in Alzheimer's disease therapy,” Expert Review of Neurotherapeutics, vol. 5, no. 5, pp. 671–682, 2005. View at Publisher · View at Google Scholar · View at PubMed
  45. M Racchi, M Mazzucchelli, S C Lenzken, E Porrello, C Lanni, and S Govoni, “Role of acetylcholinesterase inhibitors in the regulation of amyloid beta precursor protein (AbetaPP) metabolism,” Chemico-Biological Interactions, vol. 157-158, pp. 335–338, 2005, November 16; [Epub ahead of print]. View at Publisher · View at Google Scholar · View at PubMed
  46. H Kaduszkiewicz, T Zimmermann, H P Beck-Bornholdt, and H van den Bussche, “Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials,” British Medical Journal, vol. 331, no. 7512, pp. 321–327, 2005. View at Publisher · View at Google Scholar · View at PubMed
  47. N H Greig, T Utsuki, D K Ingram, et al., “Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 47, pp. 17213–17218, 2005. View at Publisher · View at Google Scholar · View at PubMed
  48. J M Ellis, “Cholinesterase inhibitors in the treatment of dementia,” The Journal of the American Osteopathic Association, vol. 105, no. 3, pp. 145–158, 2005. View at PubMed
  49. M Zimmermann, B Borroni, F Cattabeni, A Padovani, and M Di Luca, “Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients,” Neurobiology of Disease, vol. 19, no. 1-2, pp. 237–242, 2005. View at Publisher · View at Google Scholar · View at PubMed
  50. D G Wilkinson, P T Francis, E Schwam, and J Payne-Parrish, “Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy,” Drugs & Aging, vol. 21, no. 7, pp. 453–478, 2004. View at PubMed
  51. D K Lahiri, J T Rogers, N H Greig, and K Sambamurti, “Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents,” Current Pharmaceutical Design, vol. 10, no. 25, pp. 3111–3119, 2004. View at Publisher · View at Google Scholar · View at PubMed
  52. X Zhu, A K Raina, G Perry, and M A Smith, “Alzheimer's disease: the two-hit hypothesis,” Lancet Neurology, vol. 3, no. 4, pp. 219–226, 2004. View at Publisher · View at Google Scholar · View at PubMed
  53. K Herrup, R Neve, S L Ackerman, and A Copani, “Divide and die: cell cycle events as triggers of nerve cell death,” The Journal of Neuroscience, vol. 24, no. 42, pp. 9232–9239, 2004. View at Publisher · View at Google Scholar · View at PubMed
  54. R L Neve and D L McPhie, “The cell cycle as a therapeutic target for Alzheimer's disease,” Pharmacology & Therapeutics, 2005, November 7; [Epub ahead of print]. View at PubMed
  55. M X Tang, D Jacobs, Y Stern, et al., “Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease,” Lancet, vol. 348, no. 9025, pp. 429–432, 1996. View at Publisher · View at Google Scholar · View at PubMed
  56. M W Marlatt, K M Webber, P I Moreira, et al., “Therapeutic opportunities in Alzheimer disease: one for all or all for one?,” Current Medicinal Chemistry, vol. 12, no. 10, pp. 1137–1147, 2005. View at Publisher · View at Google Scholar · View at PubMed
  57. G Casadesus, X Zhu, C S Atwood, et al., “Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease,” Current Drug Targets. CNS and Neurological Disorders, vol. 3, no. 4, pp. 281–285, 2004. View at Publisher · View at Google Scholar · View at PubMed
  58. R P Koldamova, I M Lefterov, M Staufenbiel, et al., “The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease,” The Journal of Biological Chemistry, vol. 280, no. 6, pp. 4079–4088, 2005. View at Publisher · View at Google Scholar · View at PubMed
  59. E Ognibene, S Middei, S Daniele, et al., “Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease,” Behavioural Brain Research, vol. 156, no. 2, pp. 225–232, 2005. View at Publisher · View at Google Scholar · View at PubMed
  60. D M Walsh, M Townsend, M B Podlisny, et al., “Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation,” The Journal of Neuroscience, vol. 25, no. 10, pp. 2455–2462, 2005. View at Publisher · View at Google Scholar · View at PubMed
  61. N Abbas, I Bednar, E Mix, et al., “Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice,” Journal of Neuroimmunology, vol. 126, no. 1-2, pp. 50–57, 2002. View at Publisher · View at Google Scholar · View at PubMed
  62. R Tehranian, S Andell-Jonsson, S M Beni, et al., “Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist,” Journal of Neurotrauma, vol. 19, no. 8, pp. 939–951, 2002. View at Publisher · View at Google Scholar · View at PubMed
  63. P Kasa, Z Rakonczay, and K Gulya, “The cholinergic system in Alzheimer's disease,” Progress in Neurobiology, vol. 52, no. 6, pp. 511–535, 1997. View at Publisher · View at Google Scholar · View at PubMed
  64. M A Lovell, W D Ehmann, S M Butler, and W R Markesbery, “Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease,” Neurology, vol. 45, no. 8, pp. 1594–1601, 1995. View at PubMed
  65. W R Markesbery and J M Carney, “Oxidative alterations in Alzheimer's disease,” Brain Pathology, vol. 9, no. 1, pp. 133–146, 1999. View at PubMed
  66. M A Pappolla, R A Omar, K S Kim, and N K Robakis, “Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease,” The American Journal of Pathology, vol. 140, no. 3, pp. 621–628, 1992, Erratum in: The American Journal of Pathology. 1996;149(5):1770. View at PubMed
  67. M A Pappolla, Y J Chyan, B Poeggeler, et al., “Alzheimer beta protein mediated oxidative damage of mitochondrial DNA: prevention by melatonin,” Journal of Pineal Research, vol. 27, no. 4, pp. 226–229, 1999. View at Publisher · View at Google Scholar · View at PubMed
  68. P Bozner, V Grishko, S P LeDoux, G L Wilson, Y C Chyan, and M A Pappolla, “The amyloid beta protein induces oxidative damage of mitochondrial DNA,” Journal of Neuropathology and Experimental Neurology, vol. 56, no. 12, pp. 1356–1362, 1997. View at PubMed
  69. L Lyras, R H Perry, E K Perry, et al., “Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies,” Journal of Neurochemistry, vol. 71, no. 1, pp. 302–312, 1998. View at PubMed
  70. D A Butterfield, J Drake, C Pocernich, and A Castegna, “Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide,” Trends in Molecular Medicine, vol. 7, no. 12, pp. 548–554, 2001. View at Publisher · View at Google Scholar · View at PubMed
  71. L Meda, M A Cassatella, G I Szendrei, et al., “Activation of microglial cells by beta-amyloid protein and interferon-gamma,” Nature, vol. 374, no. 6523, pp. 647–650, 1995. View at Publisher · View at Google Scholar · View at PubMed
  72. L Qin, Y Liu, C Cooper, B Liu, B Wilson, and J S Hong, “Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species,” Journal of Neurochemistry, vol. 83, no. 4, pp. 973–983, 2002. View at Publisher · View at Google Scholar · View at PubMed
  73. C W Olanow, “An introduction to the free radical hypothesis in Parkinson's disease,” Annals of Neurology, vol. 32, no. suppl, pp. S2–S9, 1992. View at Publisher · View at Google Scholar · View at PubMed
  74. S Varadarajan, S Yatin, M Aksenova, and D A Butterfield, “Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity,” Journal of Structural Biology, vol. 130, no. 2-3, pp. 184–208, 2000. View at Publisher · View at Google Scholar · View at PubMed
  75. M A Smith, R K Kutty, P L Richey, et al., “Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease,” The American Journal of Pathology, vol. 145, no. 1, pp. 42–47, 1994. View at PubMed
  76. M A Smith, G Perry, P L Richey, et al., “Oxidative damage in Alzheimer's,” Nature, vol. 382, no. 6587, pp. 120–121, 1996. View at Publisher · View at Google Scholar · View at PubMed
  77. L M Sayre, D A Zelasko, P L Harris, G Perry, R G Salomon, and M A Smith, “4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease,” Journal of Neurochemistry, vol. 68, no. 5, pp. 2092–2097, 1997. View at PubMed
  78. P F Good, P Werner, A Hsu, C W Olanow, and D P Perl, “Evidence of neuronal oxidative damage in Alzheimer's disease,” The American Journal of Pathology, vol. 149, no. 1, pp. 21–28, 1996. View at PubMed
  79. C Behl, “Oxidative stress in Alzheimer's disease: implications for prevention and therapy,” Sub-Cellular Biochemistry, vol. 38, pp. 65–78, 2005. View at PubMed
  80. E Cadenas and K J Davies, “Mitochondrial free radical generation, oxidative stress, and aging,” Free Radical Biology & Medicine, vol. 29, no. 3-4, pp. 222–230, 2000. View at PubMed
  81. E Cadenas, “Mitochondrial free radical production and cell signaling,” Molecular Aspects of Medicine, vol. 25, no. 1-2, pp. 17–26, 2004. View at Publisher · View at Google Scholar · View at PubMed
  82. J F Turrens, “Mitochondrial formation of reactive oxygen species,” The Journal of Physiology, vol. 552, no. pt 2, pp. 335–344, 2003. View at Publisher · View at Google Scholar · View at PubMed
  83. F L Muller, Y Liu, and H Van Remmen, “Complex III releases superoxide to both sides of the inner mitochondrial membrane,” The Journal of Biological Chemistry, vol. 279, no. 47, pp. 49064–49073, 2004. View at Publisher · View at Google Scholar · View at PubMed
  84. A A Starkov, G Fiskum, C Chinopoulos, et al., “Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species,” The Journal of Neuroscience, vol. 24, no. 36, pp. 7779–7788, 2004. View at Publisher · View at Google Scholar · View at PubMed
  85. D C Wallace, “Mitochondrial diseases in man and mouse,” Science, vol. 283, no. 5407, pp. 1482–1488, 1999. View at Publisher · View at Google Scholar · View at PubMed
  86. S S Sheu, D Nauduri, and M W Anders, “Targeting antioxidants to mitochondria: a new therapeutic direction,” Biochimica et Biophysica Acta, vol. 1762, no. 2, pp. 256–265, 2006. View at PubMed
  87. M F Beal, “Mitochondria take center stage in aging and neurodegeneration,” Annals of Neurology, vol. 58, no. 4, pp. 495–505, 2005. View at Publisher · View at Google Scholar · View at PubMed
  88. R Jr Dawson, M F Beal, S C Bondy, D A Di Monte, and G E Isom, “Excitotoxins, aging, and environmental neurotoxins: implications for understanding human neurodegenerative diseases,” Toxicology and Applied Pharmacology, vol. 134, no. 1, pp. 1–17, 1995. View at Publisher · View at Google Scholar · View at PubMed
  89. J R Richardson, Y Quan, T B Sherer, J T Greenamyre, and G W Miller, “Paraquat neurotoxicity is distinct from that of MPTP and rotenone,” Toxicological Sciences, vol. 88, no. 1, pp. 193–201, 2005. View at Publisher · View at Google Scholar · View at PubMed
  90. S McCarthy, M Somayajulu, M Sikorska, H Borowy-Borowski, and S Pandey, “Paraquat induces oxidative stress and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10,” Toxicology and Applied Pharmacology, vol. 201, no. 1, pp. 21–31, 2004. View at Publisher · View at Google Scholar · View at PubMed
  91. M R Brown, J W Geddes, and P G Sullivan, “Brain region-specific, age-related, alterations in mitochondrial responses to elevated calcium,” Journal of Bioenergetics and Biomembranes, vol. 36, no. 4, pp. 401–406, 2004. View at Publisher · View at Google Scholar · View at PubMed
  92. A Y Abramov and M R Duchen, “The role of an astrocytic NADPH oxidase in the neurotoxicity of amyloid beta peptides,” Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, vol. 360, no. 1464, pp. 2309–2314, 2005. View at Publisher · View at Google Scholar · View at PubMed
  93. P G Sullivan, A G Rabchevsky, J N Keller, et al., “Intrinsic differences in brain and spinal cord mitochondria: implication for therapeutic interventions,” The Journal of Comparative Neurology, vol. 474, no. 4, pp. 524–534, 2004. View at Publisher · View at Google Scholar · View at PubMed
  94. S M Cardoso, S Santos, R H Swerdlow, and C R Oliveira, “Functional mitochondria are required for amyloid beta-mediated neurotoxicity,” The FASEB Journal, vol. 15, no. 8, pp. 1439–1441, 2001. View at PubMed
  95. H K Anandatheerthavarada, G Biswas, M A Robin, and N G Avadhani, “Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells,” The Journal of Cell Biology, vol. 161, no. 1, pp. 41–54, 2003. View at Publisher · View at Google Scholar · View at PubMed
  96. S Melov, N Wolf, D Strozyk, S R Doctrow, and A I Bush, “Mice transgenic for Alzheimer disease beta-amyloid develop lens cataracts that are rescued by antioxidant treatment,” Free Radical Biology & Medicine, vol. 38, no. 2, pp. 258–261, 2005. View at PubMed
  97. Z J Zhang, Y H Qian, H T Hu, J Yang, and G D Yang, “The herbal medicine Dipsacus asper wall extract reduces the cognitive deficits and overexpression of beta-amyloid protein induced by aluminum exposure,” Life Sciences, vol. 73, no. 19, pp. 2443–2454, 2003. View at Publisher · View at Google Scholar · View at PubMed
  98. A Krzepilko, A Swiecilo, J Wawryn, et al., “Ascorbate restores lifespan of superoxide-dismutase deficient yeast,” Free Radical Research, vol. 38, no. 9, pp. 1019–1024, 2004. View at Publisher · View at Google Scholar · View at PubMed
  99. H Ruan, X D Tang, M L Chen, et al., “High-quality life extension by the enzyme peptide methionine sulfoxide reductase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 5, pp. 2748–2753, 2002, Epub 2002 February 26. View at Publisher · View at Google Scholar · View at PubMed
  100. T Magwere, M West, K Riyahi, M P Murphy, R A Smith, and L Partridge, “The effects of exogenous antioxidants on lifespan and oxidative stress resistance in Drosophila melanogaster,” Mechanisms of Ageing and Development, vol. 127, no. 4, pp. 356–370, 2006, [Epub ahead of print]. View at Publisher · View at Google Scholar · View at PubMed
  101. S E Schriner, N J Linford, G M Martin, et al., “Extension of murine life span by overexpression of catalase targeted to mitochondria,” Science, vol. 308, no. 5730, pp. 1909–1911, 2005. View at Publisher · View at Google Scholar · View at PubMed
  102. G F Kelso, C M Porteous, C V Coulter, et al., “Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties,” The Journal of Biological Chemistry, vol. 276, no. 7, pp. 4588–4596, 2001. View at Publisher · View at Google Scholar · View at PubMed
  103. R A Smith, C M Porteous, C V Coulter, and M P Murphy, “Selective targeting of an antioxidant to mitochondria,” European Journal of Biochemistry, vol. 263, no. 3, pp. 709–716, 1999. View at Publisher · View at Google Scholar · View at PubMed
  104. M P Murphy, K S Echtay, F H Blaikie, et al., “Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from alpha-phenyl-N-tert-butylnitrone,” The Journal of Biological Chemistry, vol. 278, no. 49, pp. 48534–48545, 2003. View at Publisher · View at Google Scholar · View at PubMed
  105. K Zhao, G M Zhao, D Wu, et al., “Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury,” The Journal of Biological Chemistry, vol. 279, no. 33, pp. 34682–34690, 2004, Epub 2004 June 2. View at Publisher · View at Google Scholar · View at PubMed
  106. K Zhao, G Luo, S Giannelli, and H H Szeto, “Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines,” Biochemical Pharmacology, vol. 70, no. 12, pp. 1796–1806, 2005, Epub 2005 October 10. View at Publisher · View at Google Scholar · View at PubMed
  107. M P Murphy and R A Smith, “Drug delivery to mitochondria: the key to mitochondrial medicine,” Advanced Drug Delivery Reviews, vol. 41, no. 2, pp. 235–250, 2000. View at Publisher · View at Google Scholar · View at PubMed
  108. M P Murphy, “Selective targeting of bioactive compounds to mitochondria,” Trends in Biotechnology, vol. 15, no. 8, pp. 326–330, 1997. View at Publisher · View at Google Scholar · View at PubMed
  109. F L Crane, “Hydroquinone dehydrogenases,” Annual Review of Biochemistry, vol. 46, pp. 439–469, 1977. View at Publisher · View at Google Scholar · View at PubMed
  110. V E Kagan, E A Serbinova, D A Stoyanovsky, S Khwaja, and L Packer, “Assay of ubiquinones and ubiquinols as antioxidants,” Methods in Enzymology, vol. 234, pp. 343–354, 1994. View at PubMed
  111. J J Maguire, D S Wilson, and L Packer, “Mitochondrial electron transport-linked tocopheroxyl radical reduction,” The Journal of Biological Chemistry, vol. 264, no. 36, pp. 21462–21465, 1989. View at PubMed
  112. L Ernster, P Forsmark, and K Nordenbrand, “The mode of action of lipid-soluble antioxidants in biological membranes: relationship between the effects of ubiquinol and vitamin E as inhibitors of lipid peroxidation in submitochondrial particles,” BioFactors, vol. 3, no. 4, pp. 241–248, 1992. View at PubMed
  113. K U Ingold, V W Bowry, R Stocker, and C Walling, “Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 1, pp. 45–49, 1993. View at Publisher · View at Google Scholar · View at PubMed
  114. P M Hwang, F Bunz, J Yu, et al., “Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells,” Nature Medicine, vol. 7, no. 10, pp. 1111–1117, 2001. View at Publisher · View at Google Scholar · View at PubMed
  115. M L Jauslin, T Meier, R A Smith, and M P Murphy, “Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants,” The FASEB Journal, vol. 17, no. 13, pp. 1972–1974, 2003. View at PubMed
  116. B Bedogni, G Pani, R Colavitti, et al., “Redox regulation of cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival,” The Journal of Biological Chemistry, vol. 278, no. 19, pp. 16510–16519, 2003. View at Publisher · View at Google Scholar · View at PubMed
  117. A Dhanasekaran, S Kotamraju, S V Kalivendi, et al., “Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis,” The Journal of Biological Chemistry, vol. 279, no. 36, pp. 37575–37587, 2004. View at Publisher · View at Google Scholar · View at PubMed
  118. R A Smith, C M Porteous, A M Gane, and M P Murphy, “Delivery of bioactive molecules to mitochondria in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 9, pp. 5407–5412, 2003. View at Publisher · View at Google Scholar · View at PubMed
  119. V J Adlam, J C Harrison, C M Porteous, et al., “Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury,” The FASEB Journal, vol. 19, no. 9, pp. 1088–1095, 2005. View at Publisher · View at Google Scholar · View at PubMed
  120. G Hughes, M P Murphy, and E C Ledgerwood, “Mitochondrial reactive oxygen species regulate the temporal activation of nuclear factor kappaB to modulate tumour necrosis factor-induced apoptosis: evidence from mitochondria-targeted antioxidants,” The Biochemical Journal, vol. 389, no. pt 1, pp. 83–89, 2005. View at Publisher · View at Google Scholar · View at PubMed
  121. D Han, F Antunes, R Canali, D Rettori, and E Cadenas, “Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol,” The Journal of Biological Chemistry, vol. 278, no. 8, pp. 5557–5563, 2003. View at Publisher · View at Google Scholar · View at PubMed
  122. B Poeggeler, G {Durand}, A Polidori, et al., “Mitochondrial medicine: neuroprotection and life extension by the new amphiphilic nitrone LPBNAH acting as a highly potent antioxidant agent,” Journal of Neurochemistry, vol. 95, no. 4, pp. 962–973, 2005. View at Publisher · View at Google Scholar · View at PubMed
  123. J S Wright, D J Capenter, D J McKay, and K U Ingold, “Theortical calculation of substituent effects on the O-H bond strength of phenolic antioxidants related to vitamin E,” Journal of the American Chemical Society, pp. 4245–4252, 1997. View at Publisher · View at Google Scholar
  124. K Zhao, G Luo, G M Zhao, P W Schiller, and H H Szeto, “Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide,” The Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 1, pp. 425–432, 2003. View at Publisher · View at Google Scholar · View at PubMed
  125. G M Zhao, X Qian, P W Schiller, and H H Szeto, “Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors,” The Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 3, pp. 947–954, 2003. View at Publisher · View at Google Scholar · View at PubMed